Form 8-K - Current report:
SEC Accession No. 0001171843-22-002497
Filing Date
2022-04-11
Accepted
2022-04-11 08:01:11
Documents
12
Period of Report
2022-04-08
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_041122.htm   iXBRL 8-K 25432
  Complete submission text file 0001171843-22-002497.txt   198710

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE bcrx-20220408.xsd EX-101.SCH 3033
3 XBRL LABEL FILE bcrx-20220408_lab.xml EX-101.LAB 34476
4 XBRL PRESENTATION FILE bcrx-20220408_pre.xml EX-101.PRE 22595
6 EXTRACTED XBRL INSTANCE DOCUMENT f8k_041122_htm.xml XML 3592
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-23186 | Film No.: 22818507
SIC: 2836 Biological Products, (No Diagnostic Substances)